Work Pressure a Barrier to CME on the Internet: Canadian Study
June 1st 2000CLEVELAND-Distance education for continuing medical education (CME), often conducted via e-mail and the Inter-net, is designed for independent study at the participant’s convenience. It also eliminates the need for travel, an important consideration in a country like Canada with a large geographic area and a small population.
Reynolds’s Allegedly Safer ‘Eclipse’ Cigarette Casts a Dark Shadow
June 1st 2000WASHINGTON-A safer cigarette from R.J. Reynolds Tobacco Company? Leading antismoking groups don’t buy it, and Health and Human Services Secretary Donna E. Shalala expressed “significant concerns about the marketing plans” for RJR’s new Eclipse brand.
Greater HPV Persistence in HIV+ Women in Southeast US
June 1st 2000SAN DIEGO-Human immunodeficiency virus (HIV)-infected women from the southeastern United States are more likely to have contracted HIV through heterosexual contact, to be black, and to harbor multiple subtypes of human papillomavirus (HPV) than are HIV-positive women from other parts of the country, Ronald D. Alvarez, MD, said at the 31st Annual Meeting of the Society of Gynecologic Oncologists (SGO).
Oncolytic Herpesvirus Promising in Colon Cancer Liver Metastases
June 1st 2000NEW ORLEANS-A mutant her-pesvirus has been shown, in vitro and in vivo, to be highly oncolytic against colon carcinoma cells in liver metastases. On-colysis induced by the replication of this virus, combined with cyclophosphamide prodrug activation, appears to hold therapeutic promise in this setting, according to research presented at the Society of Surgical Oncology Cancer Symposium.
Quality of Life Assessment in Culturally Diverse Populations
June 1st 2000CHICAGO-While the main objective in caring for cancer patients has been to prolong life and to focus on short-term and long-term survival, more recent efforts include considerations of health-related quality of life (QOL).[1,2] The World Health Organization defines QOL as “not merely the absence of disease but a state of physical, emotional, and social well being.”[3]
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000In his excellent review, Dr. Mitsuyasu correctly highlights the three most important ingredients that play a role in the pathogenesis of acquired immunodeficiency syndrome (AIDS)-related Kaposi’s sarcoma (KS)-Kaposi’s sarcoma herpesvirus/human herpesvirus type 8 (KSHV/HHV-8); altered expression and response to cytokines; and stimulation of KS growth by the human immunodeficiency virus (HIV)-1 trans-activating protein, Tat. Recent studies have provided tremendous insight into the process whereby KSHV/HHV-8 creates the inflammatory-angiogenic state that characterizes KS.
Oral Therapy for Colorectal Cancer: How to Choose
June 1st 2000Heidelberger and associates[1] synthesized fluorouracil (5-FU) in 1957 after observing that rat hepatomas utilized radiolabeled uracil more avidly than malignant tissues. For the past 40 years, 5-FU has been extensively investigated in various schedules, in combination with biochemical modulators, and for a variety of malignancies.[2]
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000Dr. Mitsuyasu has been doing clinical research in patients with AIDS-related Kaposi’s sarcoma (KS) since the beginning of the AIDS epidemic, and his review reflects this breadth of experience. It provides a well-rounded and up-to-date assessment of the pathophysiology, evaluation, and treatment of AIDS-related KS that should be a useful guide for practicing physicians.
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000In his article, Dr. Mitsuyasu concisely reviews a large body of data concerning the etiology, pathogenesis, epidemiology, and treatment of Kaposi’s sarcoma (KS) in the setting of the human immunodeficiency virus (HIV) infection. As he correctly points out, effective highly active antiretroviral therapy (HAART), with its consequent improvements in immune function and decrease in production of viral and cytokine cofactors that promote KS growth, has been partly responsible for the decline of KS incidence in areas with ready access to HIV therapy.
Infectious Complications of Pentostatin Therapy
Managing the infectious complications associated with pentostatin (Nipent), used alone or in combination with other agents in patients with low-grade lymphomas, poses a significant problem for clinicians. Since there is limited
Pentostatin and Rituximab in the Treatment of Patients With B-Cell Malignancies
June 1st 2000Both pentostatin (Nipent) and rituximab (Rituxan) have single-agent activity in B-cell malignancies, including indolent and intermediate-grade non-Hodgkin’s lymphoma (NHL). Pentostatin is also active in pretreated patients
Tips for Caregivers on Coping With Cancer Symptoms and Drug Effects
June 1st 2000NEW YORK-Coping with cancer and the side effects of treatment can be difficult and frustrating for caregivers as well as patients. Frances K. Barg, MEd, Coordinator for Cancer Control Education, University of Pennsylvania School of Nursing, and Mary Pat Lynch, CRNP, MSN, AOCN, graduate faculty, Oncology Advanced Practice Nurse Program, University of Pennsylvania School of Nursing, had some tips for caregivers and answers to their questions at a Cancer Care, Inc. teleconference. They reviewed a number of things caregivers can do to help relieve the most common problems.
Diagnostic Evaluation of Hepatocellular Carcinoma in a Cirrhotic Liver
Hepatocellular carcinoma (HCC) is one of the world’s most common cancers. It is closely associated with cirrhosis, especially that due to viral hepatitis. The incidences of viral hepatitis and HCC are rising steadily in the United
AIDS-Related Kaposi’s Sarcoma: Current Treatment Options, Future Trends
June 1st 2000Kaposi’s sarcoma (KS) is the most common malignancy associated with the acquired immunodeficiency syndrome (AIDS). Recent years have witnessed a decline in the overall incidence of AIDS-related KS, as well as a greater
Eovist Injection and Resovist Injection: Two New Liver-Specific Contrast Agents for MRI
May 31st 2000In this short review, we describe two new liver-specific contrast agents for MRI that are in clinical development. The main differences among the liver-specific contrast agents available at present are also discussed briefly.
ASCO Urges Passage of Patient’s Bill of Rights
May 1st 2000WASHINGTON-All cancer patients should have the opportunity to participate in clinical trials, something that will occur only if Congress passes pending legislation to guarantee insurance coverage for the cost of routine patient care for study participants, speakers told a Capitol Hill briefing sponsored by the American Society of Clinical Oncology (ASCO).
RT Not Necessarily an Impedance to Breast Reconstruction
May 1st 2000NEW ORLEANS-Mastectomy patients who have undergone radiation therapy can still have attractive results from breast reconstruction, providing the surgeon does not underestimate the extent of reconstruction required, according to results of a prospective study presented at the 68th Annual Scientific Meeting of the American Society of Plastic and Reconstructive Surgeons
Radiochemotherapy/Transplant in Low-Grade Lymphomas
May 1st 2000MUNICH, Germany-Patients with low-grade lymphoma had a longer disease-free interval when they received radiochemotherapy and stem cell transplant than when they were maintained on interferon-alfa, Wolfgang Hiddemann, MD, PhD, said at the American Society of Hematology annual meeting.
Fish Oil Supplements May Improve Cancer Therapies’ Effectiveness
May 1st 2000DALLAS-A preclinical study suggests that adding fish oil to the diet of a cancer patient might increase the effectiveness of cancer therapies and improve the patient’s outcome, W. Elaine Hardman, PhD, of the University of Texas Health Science Center at San Antonio, said at the Susan G. Komen Foundation’s 1999 National Grant Conference.
Treatment of Brain Metastases Called an ‘Orphan Specialty’
May 1st 2000NEW YORK-“Brain metastases are like orphans when it comes to medical specialties. They really do not belong to any particular area,” said Raymond Sawaya, MD, professor and chair of neurosurgery, M.D. Anderson Cancer Center. But evaluation and treatment are improving, he told patients taking part in a teleconference sponsored by the National Brain Tumor Foundation, Cancer Care, Inc., and the Oncology Nursing Society.
FDA Has No Power to Regulate Tobacco: Supreme Court
May 1st 2000WASHINGTON-While acknowledging that tobacco is a major health problem, the Supreme Court has rejected the Clinton Administration’s efforts to create a new federal control effort. It ruled 5 to 4 that “Congress has clearly precluded the Food and Drug Administration (FDA) from asserting jurisdiction to regulate tobacco products.”
Saving the Rectum With Presurgical Radiation Therapy
May 1st 2000ORLANDO-“There are still too many rectums being removed in patients with invasive rectal cancer,” said W. Robert L. Rout, MD, associate professor of surgery, University of Florida, Gainesville. He believes this situation could be improved with the use of preoperative radiotherapy and chemotherapy.
Symposium Aims to Eliminate Racial Disparities
May 1st 2000WASHINGTON-Ethnic and racial disparities in health care are too often the result of racism, said Thomas Perez, director of the Office for Civil Rights in the US Department of Health and Human Services. He was one of a number of speakers at the 7th Biennial Symposium on Minorities, the Medically Underserved, and Cancer.
FDA, NIH Increase Oversight of Gene Therapy Trials
May 1st 2000ROCKVILLE, Md-Stung by the failure of several researchers to fully comply with federal gene therapy rules and reporting procedures, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have taken a series of steps to tighten the control and monitoring of such trials.